Bank Pictet & Cie Europe AG Decreases Stock Position in Stryker Co. (NYSE:SYK)

Bank Pictet & Cie Europe AG lowered its stake in Stryker Co. (NYSE:SYK) by 27.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,295 shares of the medical technology company’s stock after selling 483 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Stryker were worth $466,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. V Square Quantitative Management LLC lifted its stake in Stryker by 7.5% in the 4th quarter. V Square Quantitative Management LLC now owns 5,799 shares of the medical technology company’s stock worth $2,088,000 after purchasing an additional 403 shares in the last quarter. Figure 8 Investment Strategies LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $1,710,000. Catalyst Financial Partners LLC lifted its holdings in shares of Stryker by 5.6% in the 4th quarter. Catalyst Financial Partners LLC now owns 1,450 shares of the medical technology company’s stock valued at $522,000 after acquiring an additional 77 shares during the last quarter. Asset Management One Co. Ltd. grew its position in Stryker by 0.8% in the fourth quarter. Asset Management One Co. Ltd. now owns 133,843 shares of the medical technology company’s stock worth $49,135,000 after acquiring an additional 1,106 shares in the last quarter. Finally, Aljian Capital Management LLC increased its stake in Stryker by 7.0% during the fourth quarter. Aljian Capital Management LLC now owns 13,493 shares of the medical technology company’s stock worth $4,858,000 after acquiring an additional 888 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. UBS Group raised their target price on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $420.68.

Stryker Trading Down 0.9 %

Shares of NYSE SYK opened at $385.05 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a market cap of $146.79 billion, a PE ratio of 49.62, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The business has a fifty day simple moving average of $377.31 and a two-hundred day simple moving average of $366.66.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm earned $3.46 EPS. Analysts expect that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.